Purva Barot
Manager, Evidence Synthesis
Expertise:
Purva Barot is a Manager in the Evidence Synthesis group at EVERSANA, with deep expertise in systematic and targeted literature reviews, medical writing, and feasibility assessments for indirect treatment comparisons. She has contributed to a wide range of projects across therapeutic areas including oncology, rare diseases, and inflammatory bowel disease, and has authored multiple manuscripts and conference publications.
Before joining EVERSANA, Purva built a strong foundation in healthcare analytics, with a focus on evidence synthesis, real-world evidence, and market access. She has led and supported diverse project types such as market landscape analyses, evidence generation strategies, and stakeholder engagement initiatives. Her experience also includes collaborations with pharmaceutical companies, industry associations, patient advocacy groups, and clinicians.
Purva holds an MBA with a specialization in pharmaceuticals and a Bachelor of Pharmacy.
Articles by Purva Barot
Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms pf HAE, long-term prophylactic treatment plays a critical role in minimizing attack frequency and improving quality of life. Current […]